Companies Ocular Therapeutix, Inc
Ocular Therapeutix (OCUL): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Ocular Therapeutix, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers99th pct.Of 16 peer CEOs
CEO pay, last three years
- $18,574,830FY2024
- $35,946,958FY2025
CEO total pay was $35,946,958 in fiscal 2025, up from $18,574,830 in fiscal 2024.
FY2025: salary $819,200 · bonus $890,880 · stock awards $18,608,000 · option awards $15,567,000
Executives and directors
Donald Notman · CFOPravin Dugel · CEONadia Waheed · Chief Medical OfficerSanjay Nayak · Chief Strategy OfficerSteve Meyers · CCOAdrienne L. Graves, Ph.D · Independent DirectorCharles Warden · Lead Independent DirectorLeslie J. Williams · Independent DirectorMerilee Raines · Independent DirectorRichard L. Lindstrom, M.D · Independent DirectorSeung Suh Hong, Ph.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Ocular Therapeutix, Inc in fiscal 2025?
As disclosed, Pravin Dugel (Executive Chairman, President and Chief Executive Officer) was the highest-paid executive at Ocular Therapeutix, Inc in fiscal 2025, with total compensation of $35,946,958.
How does Ocular Therapeutix, Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Pravin Dugel's total compensation ranked at the 99th percentile of Ocular Therapeutix, Inc's disclosed peer group.
What is Ocular Therapeutix, Inc's CEO-to-median employee pay ratio?
As disclosed, Ocular Therapeutix, Inc's CEO-to-median employee pay ratio was 145:1.
How did shareholders vote on Ocular Therapeutix, Inc's executive compensation?
As disclosed, 74.32% of shareholders supported Ocular Therapeutix, Inc's executive compensation in the latest say-on-pay vote.
How much does Ocular Therapeutix, Inc spend in total on board compensation for fiscal 2025?
As disclosed, Ocular Therapeutix, Inc reported total board compensation of $1,160,880 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Pravin Dugel | $819,200 | $890,880 | $18,608,000 | $15,567,000 | $0 | $0 | $61,878 | $35,946,958 |
| Executive Chairman, President and Chief Executive Officer | ||||||||
| Nadia Waheed | 536,667 | 398,750 | 1,091,490 | 2,351,640 | 0 | 0 | 378 | 4,378,925 |
| Chief Medical Officer | ||||||||
| Donald Notman | 560,175 | 406,127 | 855,600 | 1,846,179 | 0 | 0 | 2,878 | 3,670,959 |
| Chief Financial Officer and Chief Operating Officer | ||||||||
| Sanjay Nayak | 510,000 | 332,775 | 825,840 | 1,791,912 | 0 | 0 | 2,878 | 3,463,405 |
| Chief Strategy Officer | ||||||||
| Steve Meyers | 510,000 | 295,800 | 550,560 | 1,191,031 | 0 | 0 | 2,878 | 2,550,269 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Pravin Dugel | $35,946,958 | $18,574,830 | — | ↑ +17,372,128 |
| Nadia Waheed | 4,378,925 | — | — | — |
| Donald Notman | 3,670,959 | 2,069,341 | 1,343,494 | ↑ +1,601,618 |
| Sanjay Nayak | 3,463,405 | — | — | — |
| Steve Meyers | 2,550,269 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to attract, retain, and motivate experienced executives by aligning their interests with stockholders through a pay-for-performance culture. A significant portion of executive compensation is variable and at-risk, tied to the achievement of rigorous corporate goals, individual performance, and long-term stock price appreciation.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Nadia Waheed | RSU | 2025-02-11 | — | — | 79,000 | — | $587,760 |
| Pravin Dugel | RSU | 2025-02-11 | — | — | 1,250,000 | — | 9,300,000 |
| Pravin Dugel | RSU | 2025-02-11 | — | — | 1,500,000 | — | 9,308,000 |
| Sanjay Nayak | RSU | 2025-02-11 | — | — | 111,000 | — | 825,840 |
| Donald Notman | RSU | 2025-02-11 | — | — | 115,000 | — | 855,600 |
| Sanjay Nayak | OPTION | 2025-02-11 | — | — | 334,000 | — | 1,791,912 |
| Steve Meyers | OPTION | 2025-02-11 | — | — | 222,000 | — | 1,191,031 |
| Steve Meyers | RSU | 2025-02-11 | — | — | 74,000 | — | 550,560 |
| Nadia Waheed | RSU | 2025-08-12 | — | — | 40,363 | — | 503,730 |
| Nadia Waheed | OPTION | 2025-08-12 | — | — | 122,923 | — | 1,080,134 |
| Nadia Waheed | OPTION | 2025-02-11 | — | — | 237,000 | — | 1,271,506 |
| Pravin Dugel | OPTION | 2025-02-11 | — | — | 2,750,000 | — | 15,567,000 |
| Donald Notman | OPTION | 2025-02-11 | — | — | 344,115 | — | 1,846,179 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Nadia Waheed | $1,091,490 | $0 | $2,351,640 | 0.0% |
| Pravin Dugel | 18,608,000 | 0 | 15,567,000 | 0.0% |
| Sanjay Nayak | 825,840 | 0 | 1,791,912 | 0.0% |
| Donald Notman | 855,600 | 0 | 1,846,179 | 0.0% |
| Steve Meyers | 550,560 | 0 | 1,191,031 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Steve Meyers | Option | 2,813 | 5.22 | — |
| Donald Notman | RSU | 7,356 | — | 89,302 |
| Steve Meyers | RSU | 11,111 | — | 134,888 |
| Donald Notman | RSU | 18,519 | — | 224,821 |
| Donald Notman | Option | 22,402 | 8.56 | — |
| Steve Meyers | Option | 27,085 | 3.88 | — |
| Steve Meyers | RSU | 32,206 | — | 390,981 |
| Sanjay Nayak | RSU | 33,548 | — | 406,180 |
| Nadia Waheed | RSU | 40,363 | — | 490,007 |
| Donald Notman | RSU | 41,091 | — | 498,845 |
| Donald Notman | Option | 45,141 | 3.88 | — |
| Steve Meyers | RSU | 74,000 | — | 898,360 |
| Steve Meyers | Option | 78,543 | 5.18 | — |
| Nadia Waheed | RSU | 79,000 | — | 959,060 |
| Nadia Waheed | RSU | 94,444 | — | 1,146,550 |
| Nadia Waheed | Option | 97,315 | 12.48 | — |
| Donald Notman | Option | 100,210 | 5.18 | — |
| Sanjay Nayak | RSU | 111,000 | — | 1,347,540 |
| Donald Notman | RSU | 115,000 | — | 1,396,100 |
| Sanjay Nayak | Option | 132,466 | 9.7 | — |
| Steve Meyers | Option | 175,751 | 7.44 | — |
| Nadia Waheed | Option | 187,626 | 7.44 | — |
| Sanjay Nayak | Option | 264,418 | 7.44 | — |
| Nadia Waheed | Option | 265,626 | 5.7 | — |
| Donald Notman | Option | 272,426 | 7.44 | — |
| Pravin Dugel | RSU | 356,241 | — | 4,324,766 |
| Pravin Dugel | Option | 694,681 | 9.7 | — |
| Pravin Dugel | RSU | 1,250,000 | — | 15,175,000 |
| Pravin Dugel | PSU | 1,500,000 | — | 18,210,000 |
| Pravin Dugel | Option | 2,750,000 | 7.44 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Charles WardenIndependent · Lead Independent Director · Audit · Compensation (Chair) | $105,000 | $123,480 | $270,199 | $0 | $0 | $498,679 |
| Merilee RainesIndependent · Audit (Chair) | 70,000 | 123,480 | 270,199 | 0 | 0 | 463,679 |
| Richard L. Lindstrom, M.DIndependent · Compensation · Nominating/Governance (Chair) | 67,500 | 123,480 | 270,199 | 0 | 0 | 461,179 |
| Leslie J. WilliamsIndependent · Audit · Compensation | 67,500 | 123,480 | 270,199 | 0 | 0 | 461,179 |
| Seung Suh Hong, Ph.DIndependent · Nominating/Governance | 55,000 | 123,480 | 270,199 | 0 | 0 | 448,679 |
| Adrienne L. Graves, Ph.DIndependent · Nominating/Governance | 55,000 | 123,480 | 270,199 | 0 | 0 | 448,679 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $420,000 |
| Equity awards (grant-date value) | $740,880 |
| All other compensation | $0 |
| Total cost of the board | $1,160,880 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Ocular Therapeutix as a peer
Companies that benchmark against OCUL
6 companies name OCUL as a compensation peer
- Akebia Therapeutics, Inc.AKBAFY2025
- ARDELYX, INC.ARDXFY2025
- HERON THERAPEUTICS, INC. /DE/HRTXFY2025
- RHYTHM PHARMACEUTICALS, INC.RYTMFY2025
- Tarsus Pharmaceuticals, Inc.TARSFY2025
Each company listed discloses OCUL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named OCUL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
EOLS Evolus, Inc.EYPT EyePoint, Inc.APLS Apellis Pharmaceuticals, Inc.TARS Tarsus Pharmaceuticals, Inc.ARDX Ardelyx, Inc.HROW Harrow, Inc.AURA Aura Biosciences, Inc.VCEL Vericel CorporationDAWN Day One Biopharmaceuticals, Inc.LGND Ligand Pharmaceuticals, Inc.PHAT Phathom Pharmaceuticals, Inc.ANIP ANI Pharmaceuticals, Inc.IBRX ImmunityBio, Inc.AGIO Agios Pharmaceuticals, Inc.TVTX Travere Therapeutics, Inc.GERN Geron Corporation
Peer reciprocity
The companies Ocular Therapeutix, Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ocular Therapeutix, Inc | 2025 | Pravin Dugel | $819,200 | $18,608,000 | $15,567,000 | $0 | $35,946,958 |
| 2 | Harrow, Inc. | 2025 | Mark Baum | 754,910 | 22,294,873 | 0 | 542,491 | 23,606,274 |
| 3 | ImmunityBio, Inc. | 2025 | Richard Adcock | 831,667 | 2,787,828 | 8,353,406 | 485,166 | 12,716,953 |
| 4 | Ligand Pharmaceuticals, Inc. | 2025 | Todd Davis | 724,500 | 5,520,493 | 4,441,120 | 764,400 | 11,472,095 |
| 5 | Vericel Corporation | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 6 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 7 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 8 | Geron Corporation | 2025 | Harout Semerjian | 321,538 | 0 | 9,695,400 | 203,000 | 10,221,755 |
| 9 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 10 | Ardelyx, Inc. | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 11 | Phathom Pharmaceuticals, Inc. | 2025 | Steven Basta | 525,000 | 1,986,600 | 3,983,144 | 455,701 | 6,968,070 |
| 12 | Tarsus Pharmaceuticals, Inc. | 2025 | Bobak Azamian | 726,333 | 2,648,284 | 2,651,487 | 555,700 | 6,617,979 |
| 13 | Day One Biopharmaceuticals, Inc. | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 14 | Evolus, Inc. | 2025 | David Moatazedi | 775,000 | 3,886,569 | 1,296,697 | 429,000 | 6,412,214 |
| 15 | EyePoint, Inc. | 2025 | Jay Duker | 696,251 | 1,610,700 | 2,604,113 | 632,700 | 5,568,352 |
| 16 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 17 | Aura Biosciences, Inc. | 2025 | Elisabet de los Pinos | 645,483 | 1,492,378 | 1,513,293 | 284,013 | 3,956,167 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Ocular Therapeutix, Inc | 145% | not disclosed | No | Aon |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Ardelyx, Inc. | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Aura Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance |
| Day One Biopharmaceuticals, Inc. | 123%% | Stock Options 50 · RSUs 50 | not disclosed | Compensia Inc. |
| Evolus, Inc. | 55% | not disclosed | No | Radford, an Aon Company |
| EyePoint, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Geron Corporation | 90% | Options 75 · RSU 25 | not disclosed | Aon |
| Harrow, Inc. | 100% | not disclosed | No | Mercer, Inc. |
| ImmunityBio, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Mercer |
| Ligand Pharmaceuticals, Inc. | 150% | not disclosed | No | Aon |
| Phathom Pharmaceuticals, Inc. | 124% | not disclosed | No | Pay Governance LLC |
| Tarsus Pharmaceuticals, Inc. | 108% | Options 50 · RSU 50 | No | Pay Governance |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Vericel Corporation | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-12 | 116,101,559 | 40,115,637 | 859,146 | 74.32% | Passed |
| 2025 | 2025-06-11 | 83,186,516 | 27,851,866 | 185,263 | 74.92% | Passed |
| 2024 | 2024-06-14 | 76,321,509 | 9,265,164 | 171,399 | 89.17% | Passed |
| 2023 | 2023-06-16 | 26,523,000 | 11,166,252 | 114,032 | 70.37% | Passed |
| 2022 | 2022-06-17 | 31,197,580 | 10,723,248 | 160,717 | 74.42% | Passed |
| 2021 | 2021-06-22 | 43,814,529 | 1,198,582 | 87,575 | 97.34% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-12 | 74.32%a |
| 2025 | 2025-06-11 | 74.92%b |
| 2024 | 2024-06-14 | 89.17%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Accordingly, abstentions and "broker non-votes" will have no effect on the voting on the proposals referenced above except for the approval of the Amendment of the Restated Certificate of Incorporation (Proposal 4).”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 145 : 1 |
|---|---|
| CEO total compensation | $35,946,958 |
| Median employee compensation | $247,396 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Sanjay Nayak | Chief Strategy Officer | 2026-05-26 | D | 1,858 | $8 | $15,236 | Common | Form 4 ↗ |
| Peter Kaiser | Chief Development Officer | 2026-05-26 | D | 2,967 | 8 | 24,329 | Common | Form 4 ↗ |
| Pravin Dugel | Director | 2026-05-26 | D | 21,156 | 8 | 173,479 | Common | Form 4 ↗ |
| Jeffrey S. Heier | Chief Scientific Officer | 2026-05-26 | D | 3,018 | 8 | 24,748 | Common | Form 4 ↗ |
| Pravin Dugel | Director | 2026-05-28 | A | 394,696 | 0 | 0 | Common | Form 4 ↗ |
| Pravin Dugel | Director | 2026-05-28 | D | 394,696 | 0 | 0 | Common | Form 4 ↗ |
| Nadia Waheed | Chief Medical Officer | 2026-06-03 | D | 14,828 | 8 | 122,628 | Common | Form 4 ↗ |
| Merilee Raines | Director | 2026-06-10 | A | 14,000 | 0 | 0 | RSU | Form 4 ↗ |
| Leslie J. Williams | Director | 2026-06-10 | A | 44,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie J. Williams | Director | 2026-06-10 | A | 14,000 | 0 | 0 | RSU | Form 4 ↗ |
| Richard L. Lindstrom Md | Director | 2026-06-10 | A | 44,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Merilee Raines | Director | 2026-06-10 | A | 44,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Seung Suh Hong | Director | 2026-06-10 | A | 44,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard L. Lindstrom Md | Director | 2026-06-10 | A | 14,000 | 0 | 0 | RSU | Form 4 ↗ |
| Jason Shand Robins | Chief Financial Officer | 2026-06-10 | A | 14,024 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Seung Suh Hong | Director | 2026-06-10 | A | 14,000 | 0 | 0 | RSU | Form 4 ↗ |
| Charles Warden | Director | 2026-06-10 | A | 44,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adrienne L. Graves | Director | 2026-06-10 | A | 44,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles Warden | Director | 2026-06-10 | A | 14,000 | 0 | 0 | RSU | Form 4 ↗ |
| Jason Shand Robins | Chief Financial Officer | 2026-06-10 | A | 15,441 | 0 | 0 | RSU | Form 4 ↗ |
| Adrienne L. Graves | Director | 2026-06-10 | A | 14,000 | 0 | 0 | RSU | Form 4 ↗ |
| Pravin Dugel | Director | 2026-06-16 | A | 50,092 | 0 | 0 | Common | Form 4 ↗ |
| Pravin Dugel | Director | 2026-06-16 | D | 50,092 | 0 | 0 | Common | Form 4 ↗ |
| Pravin Dugel | Director | 2026-08-24 | D | 21,649 | 11 | 233,160 | Common | Form 4 ↗ |
| Jeffrey S. Heier | Chief Scientific Officer | 2026-08-24 | D | 3,296 | 11 | 35,531 | Common | Form 4 ↗ |
| Peter Kaiser | Chief Development Officer | 2026-08-24 | D | 3,035 | 11 | 32,687 | Common | Form 4 ↗ |
| Sanjay Nayak | Chief Strategy Officer | 2026-08-24 | D | 1,897 | 11 | 20,450 | Common | Form 4 ↗ |
| Pravin Dugel | Director | 2026-08-25 | D | 50,092 | 0 | 0 | Common | Form 4 ↗ |
| Pravin Dugel | Director | 2026-08-25 | A | 50,092 | 0 | 0 | Common | Form 4 ↗ |
| Donald Notman | Chief Operating Officer | 2026-08-31 | D | 1,099 | 10 | 11,254 | Common | Form 4 ↗ |
| Jeffrey S. Heier | Chief Scientific Officer | 2026-10-02 | D | 10,869 | 7 | 76,626 | Common | Form 4 ↗ |
| Peter Kaiser | Chief Development Officer | 2026-10-02 | D | 9,990 | 7 | 70,430 | Common | Form 4 ↗ |
| Todd Anderman | Chief Legal Officer | 2026-10-08 | D | 11,984 | 7 | 87,363 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (83 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Pravin Dugel. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 35. As printed: 35,946,958. View filing ↗
- Section 01, Nadia Waheed. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 35. As printed: 4,378,925. View filing ↗
- Section 01, Donald Notman. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 35. As printed: 3,670,959. View filing ↗
- Section 01, Sanjay Nayak. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 35. As printed: 3,463,405. View filing ↗
- Section 01, Steve Meyers. DEF 14A, filed 2026-04-30. Section “Summary Compensation Table” · page 35. As printed: 2,550,269. View filing ↗
- Section 03, Nadia Waheed RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Pravin Dugel RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Pravin Dugel RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Sanjay Nayak RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Donald Notman RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Sanjay Nayak OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Steve Meyers OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Steve Meyers RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Nadia Waheed RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Nadia Waheed OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Nadia Waheed OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Pravin Dugel OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 03, Donald Notman OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Award Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-30. Section “CEO Pay Ratio”. As printed: 145 : 1. View filing ↗
- Section 08, Charles Warden. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 498,679. View filing ↗
- Section 08, Merilee Raines. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 463,679. View filing ↗
- Section 08, Richard L. Lindstrom, M.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 461,179. View filing ↗
- Section 08, Leslie J. Williams. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 461,179. View filing ↗
- Section 08, Seung Suh Hong, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 448,679. View filing ↗
- Section 08, Adrienne L. Graves, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 448,679. View filing ↗
- Section 02, Sanjay Nayak 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Kaiser 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pravin Dugel 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey S. Heier 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pravin Dugel 2026-05-28. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pravin Dugel 2026-05-28. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nadia Waheed 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Merilee Raines 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leslie J. Williams 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leslie J. Williams 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard L. Lindstrom Md 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Merilee Raines 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seung Suh Hong 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard L. Lindstrom Md 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Shand Robins 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Seung Suh Hong 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Warden 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adrienne L. Graves 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles Warden 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Shand Robins 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adrienne L. Graves 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pravin Dugel 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pravin Dugel 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pravin Dugel 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey S. Heier 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Kaiser 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sanjay Nayak 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pravin Dugel 2026-08-25. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pravin Dugel 2026-08-25. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Donald Notman 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey S. Heier 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Kaiser 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Todd Anderman 2026-10-08. Form 4, filed 2026-10-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 74.32% (votes for as printed: 116,101,559). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-11. Item 5.07 · say-on-pay result. As reported: 74.92% (votes for as printed: 83,186,516). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 89.17% (votes for as printed: 76,321,509). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 420,000 + equity 740,880 + all other 0 = 1,160,880, summed across the director compensation table rows.
- Ocular Therapeutix, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Ocular Therapeutix, Inc's own proxy. As printed: 35,946,958. View filing ↗
- Harrow, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Harrow, Inc.'s own proxy. As printed: 23,606,274. View filing ↗
- ImmunityBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in ImmunityBio, Inc.'s own proxy. As printed: 12,716,953. View filing ↗
- Ligand Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Ligand Pharmaceuticals, Inc.'s own proxy. As printed: 11,472,095. View filing ↗
- Vericel Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- ANI Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. View filing ↗
- Geron Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Geron Corporation's own proxy. As printed: 10,221,755. View filing ↗
- Travere Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. View filing ↗
- Ardelyx, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ardelyx, Inc.'s own proxy. As printed: 7,796,171. View filing ↗
- Phathom Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Phathom Pharmaceuticals, Inc.'s own proxy. As printed: 6,968,070. View filing ↗
- Tarsus Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Tarsus Pharmaceuticals, Inc.'s own proxy. As printed: 6,617,979. View filing ↗
- Day One Biopharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Day One Biopharmaceuticals, Inc.'s own proxy. As printed: 6,560,577. View filing ↗
- Evolus, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Evolus, Inc.'s own proxy. As printed: 6,412,214. View filing ↗
- EyePoint, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in EyePoint, Inc.'s own proxy. As printed: 5,568,352. View filing ↗
- Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Aura Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Aura Biosciences, Inc.'s own proxy. As printed: 3,956,167. View filing ↗
- Section 10a, Tarsus Pharmaceuticals, Inc. reciprocity. DEF 14A. Tarsus Pharmaceuticals, Inc. names Ocular Therapeutix, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Ardelyx, Inc. reciprocity. DEF 14A. Ardelyx, Inc. names Ocular Therapeutix, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗